JP5646320B2 - 遺伝子発現と疼痛 - Google Patents

遺伝子発現と疼痛 Download PDF

Info

Publication number
JP5646320B2
JP5646320B2 JP2010507728A JP2010507728A JP5646320B2 JP 5646320 B2 JP5646320 B2 JP 5646320B2 JP 2010507728 A JP2010507728 A JP 2010507728A JP 2010507728 A JP2010507728 A JP 2010507728A JP 5646320 B2 JP5646320 B2 JP 5646320B2
Authority
JP
Japan
Prior art keywords
nucleotide
seq
oligonucleotide
sequence
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010507728A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010526541A (ja
JP2010526541A5 (enExample
Inventor
ジュリアン マメ，
ジュリアン マメ，
Original Assignee
アダイニクス， インコーポレイテッド
アダイニクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アダイニクス， インコーポレイテッド, アダイニクス， インコーポレイテッド filed Critical アダイニクス， インコーポレイテッド
Publication of JP2010526541A publication Critical patent/JP2010526541A/ja
Publication of JP2010526541A5 publication Critical patent/JP2010526541A5/ja
Application granted granted Critical
Publication of JP5646320B2 publication Critical patent/JP5646320B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
JP2010507728A 2007-05-11 2008-05-12 遺伝子発現と疼痛 Expired - Fee Related JP5646320B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91758307P 2007-05-11 2007-05-11
US60/917,583 2007-05-11
PCT/US2008/063471 WO2008141308A2 (en) 2007-05-11 2008-05-12 Gene expression and pain

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014149516A Division JP5890869B2 (ja) 2007-05-11 2014-07-23 遺伝子発現と疼痛

Publications (3)

Publication Number Publication Date
JP2010526541A JP2010526541A (ja) 2010-08-05
JP2010526541A5 JP2010526541A5 (enExample) 2012-04-05
JP5646320B2 true JP5646320B2 (ja) 2014-12-24

Family

ID=40002879

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2010507728A Expired - Fee Related JP5646320B2 (ja) 2007-05-11 2008-05-12 遺伝子発現と疼痛
JP2014149516A Expired - Fee Related JP5890869B2 (ja) 2007-05-11 2014-07-23 遺伝子発現と疼痛
JP2015207655A Expired - Fee Related JP6082796B2 (ja) 2007-05-11 2015-10-22 遺伝子発現と疼痛
JP2016064037A Expired - Fee Related JP6306075B2 (ja) 2007-05-11 2016-03-28 遺伝子発現と疼痛
JP2017106521A Pending JP2017148074A (ja) 2007-05-11 2017-05-30 遺伝子発現と疼痛

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2014149516A Expired - Fee Related JP5890869B2 (ja) 2007-05-11 2014-07-23 遺伝子発現と疼痛
JP2015207655A Expired - Fee Related JP6082796B2 (ja) 2007-05-11 2015-10-22 遺伝子発現と疼痛
JP2016064037A Expired - Fee Related JP6306075B2 (ja) 2007-05-11 2016-03-28 遺伝子発現と疼痛
JP2017106521A Pending JP2017148074A (ja) 2007-05-11 2017-05-30 遺伝子発現と疼痛

Country Status (13)

Country Link
US (5) US7943591B2 (enExample)
EP (3) EP3199635B1 (enExample)
JP (5) JP5646320B2 (enExample)
AU (1) AU2008251320B2 (enExample)
CA (1) CA2723672C (enExample)
DK (1) DK2158316T3 (enExample)
ES (2) ES2619314T3 (enExample)
HR (1) HRP20150759T1 (enExample)
HU (1) HUE025701T2 (enExample)
PL (1) PL2158316T3 (enExample)
PT (1) PT2158316E (enExample)
SI (1) SI2158316T1 (enExample)
WO (1) WO2008141308A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3199635B1 (en) 2007-05-11 2019-02-06 Adynxx, Inc. Gene expression and pain
RU2015151857A (ru) 2008-12-02 2019-01-15 Уэйв Лайф Сайенсес Джапан, Инк. Способ синтеза модифицированных по атому фосфора нуклеиновых кислот
MX342945B (es) 2009-07-06 2016-10-18 Ontorii Inc * Profármacos de ácido nucleico novedosos y métodos de uso de los mismos.
US8609617B2 (en) 2009-09-04 2013-12-17 University Of Miami KLF family members regulate intrinsic axon regeneration ability
US10428019B2 (en) 2010-09-24 2019-10-01 Wave Life Sciences Ltd. Chiral auxiliaries
EP3248982A1 (en) 2011-07-19 2017-11-29 Wave Life Sciences Ltd. Thiosulfonate reagents for the synthesis of functionalized nucleic acids
CA2848740A1 (en) 2011-09-16 2013-03-21 Mingxing Wang Amphiphilic cationic polymers for the delivery of therapeutic agents
US9139829B2 (en) * 2012-02-28 2015-09-22 Medical Diagnostic Laboratories, Llc SiRNA targeting ETS1 and ELK1 and method of using same in the inhibition of CIP2A gene in cancer treatment
CA2872901A1 (en) * 2012-05-10 2013-11-14 Adynxx, Inc. Formulations for the delivery of active ingredients
CA2879066C (en) 2012-07-13 2019-08-13 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
CN104661664B (zh) 2012-07-13 2020-07-03 波涛生命科学有限公司 手性控制
CA2879023C (en) 2012-07-13 2017-03-28 Wave Life Sciences Japan Asymmetric auxiliary group
GB201310853D0 (en) * 2013-06-18 2013-07-31 Ucb Pharma Sa Method
US10144933B2 (en) 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
MX2016009290A (es) 2014-01-16 2017-02-28 Wave Life Sciences Ltd Diseño quiral.
CA2957250A1 (en) 2014-08-15 2016-02-18 Adynxx, Inc. Oligonucleotide decoys for the treatment of pain
WO2017043639A1 (ja) * 2015-09-09 2017-03-16 アンジェスＭｇ株式会社 キメラデコイ
WO2017151644A1 (en) * 2016-02-29 2017-09-08 Adynxx, Inc. Compositions and methods for pain amelioration via modification of gene expression
WO2024044770A1 (en) * 2022-08-26 2024-02-29 Core Biotherapeutics, Inc. Oligonucleotides for the treatment of breast cancer

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410516B1 (en) * 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
US5206152A (en) * 1988-04-08 1993-04-27 Arch Development Corporation Cloning and expression of early growth regulatory protein genes
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5272056A (en) 1991-01-03 1993-12-21 The Research Foundation Of State University Of New York Modification of DNA and oligonucleotides using metal complexes of polyaza ligands
WO1992018522A1 (en) * 1991-04-18 1992-10-29 The Salk Institute For Biological Studies Oligodeoxynucleotides and oligonucleotides useful as decoys for proteins which selectively bind to defined dna sequences
FR2675803B1 (fr) 1991-04-25 1996-09-06 Genset Sa Oligonucleotides fermes, antisens et sens et leurs applications.
CA2168245A1 (en) * 1993-07-29 1995-02-09 C. Anthony Hunt Polynucleotide decoys that inhibit mhc-ii expression and uses thereof
EP0732929B1 (en) * 1993-10-29 2008-05-14 The Brigham And Women's Hospital, Inc. Therapeutic use of cis-element decoys in vivo
WO1996016074A1 (en) 1994-11-17 1996-05-30 Taiho Pharmaceutical Co., Ltd. Double-stranded oligonucleotide and carcinostatic agent containing the same as active ingredient
AU5369396A (en) 1995-03-23 1996-10-08 Research Foundation Of The State University Of New York, The Rest protein and dna
JP4173539B2 (ja) * 1995-05-11 2008-10-29 ラボラトアール・セローノ・ソシエテ・アノニム Ｉｌ−６活性阻害剤
PT824918E (pt) * 1995-05-12 2007-06-22 Anges Mg Inc Tratamento e prevenção para doenças causadas pelo nf-kb
GB9515356D0 (en) 1995-07-26 1995-09-20 Medical Res Council Improvements in or relating to delivery of nucleic acid
US6265389B1 (en) 1995-08-31 2001-07-24 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of oligonucleotides
CA2255822A1 (en) * 1996-05-20 1997-11-27 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Oligonucleotides which specifically bind retroviral nucleocapsid proteins
US6022863A (en) * 1996-05-21 2000-02-08 Yale University Regulation of gene expression
EP1008352A4 (en) * 1997-07-04 2005-03-16 Fujisawa Pharmaceutical Co Cerebrospinal PROTECTOR
JP3667047B2 (ja) 1997-09-12 2005-07-06 キヤノン株式会社 人工核酸およびその製造方法、デオキシリボフラノース化合物、リボフラノース化合物およびこれらの製造方法
AU9692198A (en) 1997-10-10 1999-05-03 Kevin J. Donahue Gene delivery compositions and methods
US6060310A (en) * 1997-11-24 2000-05-09 The United States Of America As Represented By The Department Of Health And Human Services Transcription factor decoy and tumor growth inhibitor
US6432641B1 (en) 1997-12-16 2002-08-13 University Of Saskatchewan Technologies Inc. Conductive metal-containing nucleic acids
US6689758B1 (en) 1998-06-02 2004-02-10 Smithkline Beecham Corporation Gene therapy method
US6818626B1 (en) 1998-07-17 2004-11-16 Mirus Corporation Chelating systems for use in the delivery of compounds to cells
US6867289B1 (en) * 1998-10-26 2005-03-15 Board Of Regents, The University Of Texas Systems Thio-modified aptamer synthetic methods and compositions
US6008048A (en) * 1998-12-04 1999-12-28 Isis Pharmaceuticals Inc. Antisense inhibition of EGR-1 expression
US7160869B2 (en) 1998-12-16 2007-01-09 University Of Saskatchewan Biologically active metal-containing nucleic acids
ATE354667T1 (de) 1998-12-23 2007-03-15 Genentech Inc Transfectaconen, die kalciumphosphat und eine nucleinsäure enthalten
US6395029B1 (en) 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
US6333408B1 (en) * 1999-03-08 2001-12-25 Kureha Chemical Industry Co., Ltd. Oligonucleotides inhibitors of PAI-1 MRNA
FR2790955B1 (fr) * 1999-03-19 2003-01-17 Assist Publ Hopitaux De Paris Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
US6599741B1 (en) * 1999-09-14 2003-07-29 Avontec Gmbh Modulating transcription of genes in vascular cells
US6927027B2 (en) 1999-12-21 2005-08-09 Ingeneus Corporation Nucleic acid multiplex formation
US6969704B1 (en) * 2000-08-25 2005-11-29 The Trustees Of Columbia University In The City Of New York Methods for suppressing early growth response—1protein (Egr-1) to reduce vascular injury in a subject
DE10049549A1 (de) 2000-10-06 2002-05-02 Markus Hecker Modulation der Transkription pro-inflammatorischer Genprodukte
CA2462081A1 (en) 2000-10-11 2002-04-18 Laura Kragie Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase
WO2002041922A1 (fr) 2000-11-24 2002-05-30 Chugai Seiyaku Kabushiki Kaisha Procede servant a reguler l'activite de l'expression d'un produit genetique transfere dans un organisme vivant
US20020137715A1 (en) 2001-01-03 2002-09-26 Alain Mauviel Blocking Sp1 transcription factor broadly inhibits extracellular matrix gene expression in vitro and in vivo: implications for the treatment of tissue fibrosis
US7060690B2 (en) * 2001-01-22 2006-06-13 Genta Incorporated Methods and compositions for treating a cell-proliferative disorder using CRE decoy oligomers, BCL-2 antisense oligomers, and hybrid oligomers thereof
EP1362600B1 (en) 2001-02-20 2008-04-02 AnGes MG, Inc. TOPICAL USE OF NF-kB DECOYS FOR TREATING ATOPIC DERMATITIS
AU2002254132A1 (en) 2001-03-06 2002-09-19 Sierra Sciences, Inc. Methods and compositions for modulating telomerase reverse transcriptase (tert) expression
US20030166555A1 (en) * 2001-04-02 2003-09-04 Alberini Cristina M. Methods and compositions for regulating memory consolidation
EP1298141A1 (en) 2001-09-27 2003-04-02 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Interleukin-4 (IL-4) promoter sequences specifically interacting with IRF-1 and IRF-2
DE10148828B4 (de) * 2001-10-04 2005-05-19 Avontec Gmbh Modulation der Expression STAT-1-abhängiger Gene
US6663880B1 (en) 2001-11-30 2003-12-16 Advanced Cardiovascular Systems, Inc. Permeabilizing reagents to increase drug delivery and a method of local delivery
KR20040094413A (ko) 2002-02-01 2004-11-09 오메로스 코포레이션 연골 분해를 전신 억제하기 위한 조성물 및 방법
CN1240439C (zh) 2002-03-28 2006-02-08 南京凯基生物科技发展有限公司 肿瘤基因开关药物
CN1665929A (zh) 2002-04-26 2005-09-07 安琪士多摩奇株式会社 含有转录dna结合位点的环状哑铃状诱饵寡脱氧核苷酸(cdodn)
DE10242319A1 (de) * 2002-09-12 2004-03-25 Avontec Gmbh Funkionelle Korrektur der-786C/T-Varianz des humanen eNOS-Gens
NZ541142A (en) 2002-12-09 2008-07-31 Abraxis Bioscience Inc Compositions and methods of delivery of pharmacological agents
DE10257421A1 (de) * 2002-12-09 2004-07-08 Grünenthal GmbH Regulatorische Elemente im 5'-Bereich des VR1-Gens
US20050158733A1 (en) 2003-06-30 2005-07-21 Gerber David J. EGR genes as targets for the diagnosis and treatment of schizophrenia
WO2005027830A2 (en) * 2003-09-12 2005-03-31 Virginia Commonwealth University Chimeric transcription factor decoy oligonucleotides
JP2005336081A (ja) * 2004-05-26 2005-12-08 Anges Mg Inc Ｎｒ２ｂ−ｎｍｄａ受容体の再発現抑制剤
US7482158B2 (en) * 2004-07-01 2009-01-27 Mathison Brian H Composite polynucleic acid therapeutics
US20060293264A1 (en) * 2004-07-22 2006-12-28 Grandis Jennifer R STAT3 decoy oligonucleotides and uses therefor
JP2008513513A (ja) * 2004-09-21 2008-05-01 アネシヴァ， インコーポレイテッド ポリヌクレオチドの送達
JP4991547B2 (ja) 2004-09-28 2012-08-01 クアーク・ファーマスーティカルス、インコーポレイテッド 脱毛症、急性腎不全および他の疾患の治療のためのオリゴリボヌクレオチドおよびその使用の方法
EP1803811B1 (en) * 2004-10-22 2011-05-11 AnGes MG, Inc. Chimeric (double) decoy
US7585848B2 (en) * 2005-01-11 2009-09-08 Rush University Medical Center Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc
WO2006096498A2 (en) * 2005-03-04 2006-09-14 Dana-Farber Cancer Institute, Inc. Regulation of runx1 for treatment of pain
US7680060B2 (en) * 2005-03-08 2010-03-16 Cisco Technology, Inc. Transferring state information in a network
WO2006104913A2 (en) * 2005-03-25 2006-10-05 Medtronic, Inc. USE OF ANTI-TNF OR ANTI-ILl RNAI TO SUPPRESS PRO- INFLAMMATORY CYTOKINE ACTIONS LOCALLY TO TREAT PAIN
WO2008105959A2 (en) 2006-10-09 2008-09-04 Neurofluidics, Inc. Cerebrospinal fluid purification system
MX2009011218A (es) 2007-04-17 2010-02-11 Baxter Int Microparticulas de acido nucleico para administracion pulmonar.
EP3199635B1 (en) 2007-05-11 2019-02-06 Adynxx, Inc. Gene expression and pain
SI2605794T1 (sl) 2010-08-20 2017-01-31 Replicor Inc. Oligonukleotidni kelatni kompleksi
CA2839896A1 (en) 2011-06-21 2012-12-27 Alnylam Pharmaceuticals, Inc. Assays and methods for determining activity of a therapeutic agent in a subject
MY166036A (en) 2011-07-20 2018-05-21 Hospira Inc Methods of treating pain
CA2872901A1 (en) 2012-05-10 2013-11-14 Adynxx, Inc. Formulations for the delivery of active ingredients
MY168778A (en) 2012-05-18 2018-12-04 Replicor Inc Oligonucleotide chelate complex-polypeptide compositions and methods
CA2957250A1 (en) 2014-08-15 2016-02-18 Adynxx, Inc. Oligonucleotide decoys for the treatment of pain
WO2017151644A1 (en) 2016-02-29 2017-09-08 Adynxx, Inc. Compositions and methods for pain amelioration via modification of gene expression

Also Published As

Publication number Publication date
JP2017148074A (ja) 2017-08-31
JP2014198053A (ja) 2014-10-23
JP2016014070A (ja) 2016-01-28
EP2158316A2 (en) 2010-03-03
EP2818550A1 (en) 2014-12-31
PT2158316E (pt) 2015-07-20
HUE025701T2 (en) 2016-04-28
ES2542511T3 (es) 2015-08-06
DK2158316T3 (en) 2015-07-20
US20140343132A1 (en) 2014-11-20
SI2158316T1 (sl) 2015-08-31
US9290762B2 (en) 2016-03-22
WO2008141308A2 (en) 2008-11-20
JP5890869B2 (ja) 2016-03-22
EP3199635A1 (en) 2017-08-02
US20080300209A1 (en) 2008-12-04
WO2008141308A3 (en) 2009-03-05
HRP20150759T1 (hr) 2015-08-14
JP2010526541A (ja) 2010-08-05
CA2723672C (en) 2019-09-03
EP2158316B1 (en) 2015-04-15
US7943591B2 (en) 2011-05-17
US20120232131A1 (en) 2012-09-13
AU2008251320B2 (en) 2013-12-19
US10041069B2 (en) 2018-08-07
JP6306075B2 (ja) 2018-04-04
US8741864B2 (en) 2014-06-03
US20110166212A1 (en) 2011-07-07
EP2158316A4 (en) 2011-11-09
JP6082796B2 (ja) 2017-02-15
AU2008251320A1 (en) 2008-11-20
HK1205530A1 (en) 2015-12-18
US20160222382A1 (en) 2016-08-04
EP2818550B1 (en) 2016-12-28
ES2619314T3 (es) 2017-06-26
EP3199635B1 (en) 2019-02-06
JP2016117775A (ja) 2016-06-30
US8093225B2 (en) 2012-01-10
PL2158316T3 (pl) 2015-10-30
CA2723672A1 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
JP6306075B2 (ja) 遺伝子発現と疼痛
JP7049249B2 (ja) 中枢神経系疾患の処置のための組成物および方法
CN102858990B (zh) 针对β-NGF的适体及其在治疗β-NGF介导的疾病和失调中的用途
CA2775111A1 (en) Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
JP6705807B2 (ja) 疼痛を治療するためのオリゴヌクレオチドデコイ
CN104487096B (zh) 用于活性成分递送的配制物
AU2014201462B2 (en) Gene expression and pain
AU2016266076B2 (en) Gene expression and pain
US20220348916A1 (en) Composition for diagnosis or treatment of a condition associated with increased activity of eif4e comprising an eif4e inhibitor
HK1205530B (en) Gene expression and pain

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130510

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130809

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140723

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140819

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141014

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141105

R150 Certificate of patent or registration of utility model

Ref document number: 5646320

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees